Epithelial-mesenchymal transition (EMT) has a crucial role during embryonic development and has also come under intense scrutiny as a mechanism through which esophageal squamous cell cancer (ESCC) progresses to become metastatic. Transforming growth factor beta (TGF-b)-mediated EMT has been observed in a variety of cell types and has been identified as the main inducer of EMT in many types of cancer. Akt activity is involved in TGF-b-mediated EMT; however, its precise relationship and role in EMT in ESCC has not been well explained to date. Our data demonstrated that in human ESCC tissues Akt and its activated form, phosphorylated-Akt (p-Akt), were overexpressed; in addition, Akt and p-Akt were negatively correlated with epithelial cadherin (E-cadherin). In EC-9706 cells, exogenous TGF-b1 could induce EMT and at the same time could increase the EC-9706 cell invasive and metastatic ability. Moreover, Akt knockdown by small-interfering RNA could attenuate the EMT induced by TGF-b1 by increasing the epithelial marker E-cadherin and decreasing the mesenchymal marker Vimentin. Silencing Akt expression could decrease the migration ability of EC-9706 cells efficiently. In short, Akt is likely to have a more important role in the EMT induced by TGF-b1 in EC-9706 and may contribute to the invasive and metastatic ability of EC-9706. Akt may be an effective therapeutic in advanced and metastatic ESCC.
INTRODUCTION
Esophageal squamous cell cancer is one of the most common types of malignant tumors in China, and the occurrence of invasion and metastasis accounts for poor prognosis and high mortality. 1 Therefore, there is an urgent need to understand the molecular mechanism and pathways that participate in the invasion and metastasis of esophageal squamous cell cancer for better and improved treatment of patients diagnosed with esophageal squamous cell cancer (ESCC).
Oncogenic epithelial-mesenchymal transition (EMT) is considered an important and essential evolutionary step in the development of tumor invasion and metastasis, during which epithelial cells modulate their phenotype and acquire mesenchymal-like properties through the disruption of intercellular adhesion and the enhancement of cell motility. 2 Expression of epithelial cadherin (E-cadherin) is a hallmark of a fully differentiated epithelium where it functions to maintain cell-cell junctions, thereby inhibiting cell proliferation and migration. Indeed, loss of E-cadherin function is a common characteristic of EMT. 3, 4 Recently, EMT, its accompanying reduction in E-cadherin expression and at the same time the upregulation of mesenchymal cell-specific proteins like Vimentin were shown to be essential for the invasion and metastasis of ESCC, but the specific impact of EMT in facilitating the invasion and metastasis of ESCC remains unknown.
In many human cancers, Akt is activated, endowing tumor cells with motile and invasive properties. Akt, also known as Protein Kinase B, is an evolutionarily conserved serine/threonine kinase. Three Akt isoforms have been cloned in humans, each with significant homology but different tissue distributions. 5 Akt is a downstream component in phosphoinositide 3-kinase signaling, which is activated upon autophosphorylation of receptor tyrosine kinases induced by ligands (such as insulin or other growth factors), stimulation of G-protein-coupled receptors or activation of integrin signaling. 6 The function of Akt is pleiotropic and it has emerged as an important factor in the signaling cascades that regulate cell growth, proliferation, differentiation, protein synthesis and survival, as well as angiogenesis, invasion and metastasis. 7 EMT is triggered by many signaling pathways, such as transforming growth factor beta (TGF-b1), epidermal growth factor, fibroblast growth factor, hepatocyte growth factor, bone morphogenetic proteins and Wnts and Notch. [8] [9] [10] TGF-b1-mediated EMT has been observed in a variety of cell types and the TGF-b1 signaling pathway occupies a central position in these pathways; it has been identified as the main inducer of EMT in many types of cancer. cellular morphology and increase the invasive potential of ESCC. These findings might help us to further understand the molecular mechanisms behind the pathogenesis of ESCC.
MATERIALS AND METHODS

Tissue specimens
Paraffin-embedded tissues of 80 patients with ESCC were obtained from archives of the Department of Pathology, the First Affiliated Hospital of Zhengzhou University. The diagnosis of ESCC was confirmed for all the cases by a board-certified pathologist (Li SS). Informed consent was obtained from all patients and none of the patients had received prior radiotherapy or chemotherapy. The study was approved by the Research Ethics Committee of Zhengzhou University.
Immunohistochemical staining and evaluation
Immunohistochemical staining was performed as described. The primary antibodies were purchased from Santa Cruz Biotech (Santa Cruz, CA, USA) and prepared as follows: anti-Akt, 1:200; anti-phosphorylated-Akt (p-Akt), 1:250; and anti-E-cadherin, 1:200. At least five thin sections of tumor tissues were used for immunohistochemical analysis. Negative controls were created by replacing the primary antibodies with phosphate-buffered saline. For Akt and p-Akt, cytoplasmic immunoreactivity was scored by its extent and intensity. For E-cadherin, plasma-lemmal immunoreactivity was scored by its extent and intensity. Staining intensity was graded as follows: negative (0), weak (1), moderate (2) and strong (3). Staining extent was rated according to the percentage of positive cells. Samples with no stained tumor cells were rated as 0, those with staining in 10% of tumor cells were rated as 1, those with staining in 11-50% of tumor cells were rated as 2, those with staining in 50-75% of tumor cells were rated as 3 and those with staining in 75% of tumor cells were rated as 4. The score of staining intensity multiplied by the score of extent equals an overall staining score. An overall staining score of 0-3 was regarded as negative (2) and a score of 3 as positive ( þ ) for protein expression.
Cell culture and transfection
The human ESCC cell line EC-9706 was cultured in RPMI-1640 medium (Gibco/Life Technologies, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum, 100 lg ml À 1 streptomycin and 100 U ml À 1 penicillin at 37 1C with 5% CO 2 and saturated moisture. The experimental cells were in logarithmic phase. In group1, EC-9706 cells were treated with 5 ng ml Western blot analysis EC-9706 cells were harvested and lysed in modified radioimmune precipitation assay lysis buffer with 150 mM NaCl, 1% Nonidet P-40, 1 mM EDTA, 0.5% deoxycholic acid, 2 mg ml À 1 aprotinin, 1 mM phenylmethylsulfonyl fluoride, 5 mM benzamidine, 1 mM sodium orthovanadate and 10 mg ml À 1 soybean trypsin inhibitor (Sigma, St Louis, MI, USA) in 50 mM Tris buffer of pH 7.4. The proteins were separated by SDS-polyacrylamide gel electrophoresis and then transferred onto a nitrocellulose membrane (Akt 18 min, E-cadherin 30 min, vimentin 22 min and b-actin 15 min; Yili, Beijing, China). After blocking with 0.1% Tween 20 and 5% nonfat dry milk in Tris-buffered saline at room temperature for 1 h, the membrane was incubated with primary antibody (p-Akt, E-cadherin and Vimentin) at 4 1C overnight and then incubated with horseradish peroxidase-conjugated secondary antibody for 1 h. The levels of p-Akt, E-cadherin and Vimentin were quantitated by densitometric scanning of the X-ray films with UVP's gel documentation system GDS8000 and 1D gel analysis software (UVP LLC, Upland, CA, USA).
Invasion assay
The invasion of EC-9706 cells was measured using Boyden transwell chambers (Corning, NY, USA) according to the manufacturer's protocol. Briefly, the cells were seeded onto the membrane of the upper chamber at a concentration of 3 Â 10 4 in 400 ml medium, and RPMI-1640 medium was added to the lower chamber. After 24 h, the lower chamber was washed three times with deionized water. The membrane in the lower chamber was stained with crystal violet. The number of invaded cells was counted with a microscope at least in three fields.
RESULTS
Expression of Akt, p-Akt and E-cadherin protein in ESCC Akt staining was seen predominantly in the cytoplasm (Figure 1a ) in 72.5% (58/80) of ESCCs, significantly higher than that in the normal esophageal mucosa (Figure 1b ) (32.5%, 26/80, P ¼ 0.000, Table 2 ). Akt is known to become active after phosphorylation at Thr308 and Ser473 residues; thus, the expression of p-Akt, the active form of Akt, was also examined. P-Akt staining also occurred predominantly in the cytoplasm ( Figure 1c ) and followed a similar pattern: 81.3% (65/80) in ESCCs and 15.0% (12/80) in normal esophageal mucosa ( Figure 1d ) (P ¼ 0.000, Table 2 ). E-cadherin protein showed staining in the membrane or cytoplasm of the cells (Figure 1e ), and was expressed in a reverse pattern: 33.8% Table 1 . Sequences of primers for genes Akt, E-cadherin and Vimentin
Gene
Primer sequence Amplicatin fragment (bp) Annealing temperature ( 1C)
Abbreviation: E-cadherin, epithelial cadherin.
The role of Akt in EMT X Xuan et al (27/80) in ESCCs but 86.3% (69/80) in normal esophageal mucosa ( Figure 1f ) (P ¼ 0.000, Table 2 ). In contrast, the positive rates of Vimentin were 85.0% (68/80) in ESCC tissues ( Figure 1g ) and 38.8% (31/80) in the corresponding normal tissues ( Figure 1h ) (P ¼ 0.000, Table 2 ). Expression of Akt and p-Akt was negatively correlated with that of E-cadherin (both Po0.05) and positively correlated with that of Vimentin (both Po0.05). In ESCCs with lymph node metastasis, Akt protein showed a significantly higher expression in ESCCs with lymph node metastasis compared with ESCCs without lymph node metastasis (90.0% vs 66.7%, P ¼ 0.002).
TGF-b1 induced EC-9706 morphological changes and EMT EC-9706, a well-characterized ESCC cell line, has been used as a model system for studying many types of mechanisms, which include tumor progression, apoptosis, invasion, metastasis and so on in ESCC. The general morphology of the human EC-9706 cells was observed as shown in Figure 2aA . We exposed EC-9706 to 5 ng ml À 1 TGF-b1 for 24 h, and found that the volume of EC-9706 cells increased and cell elongation was seen in some cells, the morphology of which switched from polygon to a long spindlelike shape; in addition, cells exhibited a loose connection and the gap between cells widened (Figure 2aB ).
To further study the effects of TGF-b1 on EC-9706, we investigated the expression levels of epithelial marker E-cadherin and the mesenchymal markerVimentin by reverse transcription-PCR and western blot. The results (Figure 2b, c) showed that TGF-b1 stimulation for 24 h could decrease the mRNA and protein expression of E-cadherin (mRNA expression: 0.452 ± 0.122, protein expression: 0.282 ± 0.032) greatly compared with that in control groups (mRNA expression: 0.661±0.060, protein expression: 0.428 ± 0.032, Po0.05) while increasing the expression of Vimentin at the same time (mRNA expression: 0.687 ± 0.134, protein expression: 0.677±0.070 in TGF-b1 stimulate group; mRNA expression: 0.542±0.073, protein expression: 0.577±0.049 in control group, Po0.05). These results indicated that expression of TGF-b1 could induce EMT in EC-9706 cells, which was accompanied by loss of the epithelial marker E-cadherin and acquisition of the mesenchymal marker Vimentin.
TGF-b1 can enhance the migratory and invasive capability of EC-9706 cells EMT is thought to have a significant role in invasion and metastasis in many types of cancer. In this study we found that the number of EC-9706 cells treated with TGF-b1 that could traverse the membrane of the Boyden chamber increased significantly (114.2 ± 6.22) compared with control groups (83.5 ± 10.15) (Figure 3b ). Together, we can say that TGF-b1 can change the invasive and metastatic ability of EC-9706 cells by inducing EMT (Figure 3aA, C) .
Expression of TGF-b1 induces activation of the AKT signaling pathway As we know EMT is triggered by many signaling pathways and the TGF-b1 signaling pathway is one of the most important. To identify the potential mechanisms by which TGFb1 induced EMT in ESCC, we studied the effects of TGF-b1 stimulation on the expression of Akt in EC-9706. Akt has an important role in a variety of human tumors. We found that the phosphorylation of Akt was significantly higher in cells treated with TGF-b1 (mRNA expression: 1.007±0.173, protein expression: 0.747±0.078) compared with control groups (untreated EC-9706 (Figures 4a and b) . These data show that TGF-b1-induced EMT in EC-9706 cells was associated with rapid Akt phosphorylation and activation. (Figures 5a and b) .
Compared with the cells treated with TGF-b1 alone the cells treated with TGF-b1 for 24 h and then transfected with Akt siRNA showed epithelial morphology (Figure 2aB, C) . These results showed that decreasing Akt levels reversed TGF-b1-induced morphological transition.
We all know that E-cadherin is a Ca2 þ -dependent cell adhesion molecule that plays a significant role in the maintenance of epithelial polarity. EC-9706 with TGF-b1 stimulation alone decreased the expression of E-cadherin (mRNA expression: 0.501±0.070, protein expression: 0.229±0.063), but the expression of those mRNA and proteins increased after the cells were (Figures 5c and d) . We found that knockdown of Akt expression and inhibition of Akt pathway suppressed the expression of mesenchymal marker Vimentin and the re-expression of epithelial marker E-cadherin, suggesting that the activation of the Akt pathway is critical for the maintenance of EMT in ESCC.
Inhibition of Akt activity in EC-9706 cells treated with TGF-b1 attenuated the cell migratory and invasive capability EMT can increase cell motility. Next, we investigated the role of decreased expression of Akt in aggressive behavior, such as metastatic and invasive capabilities, of EC-9706 cells. We found that cells treated with TGF-b1 alone had increased migratory and invasive ability (114.20 ± 6.22), whereas cells treated with TGF-b1 for 24 h and then transfected with Akt siRNA showed significant reduction in cell migration and invasion characteristics (85.80±14.29) (Po0.05) (Figure 3aC, D, 3b) . The number of migrated cells among cells treated with Akt siRNA alone was 68.8 ± 10.43, whereas the number of migrated cells in the untreated EC-9706 group was 83.5±10.15 (Figure 3aA, B, 3b) . The data clearly suggest the reversal of EMT morpholology and surface markers by the knockdown of Akt protein in EC-9706. These data further confirm the role of Akt in the process of cell migration and invasion, perhaps because of the association of Akt with EMT.
DISCUSSION
The spread of cancer cells from the primary tumor is a major complicating factor of cancer progression, preventing effective The role of Akt in EMT X Xuan et al treatment and substantially decreasing patient prognosis. EMT is a critical mechanism of migration and invasion during development. Recently, an analogous process has been observed, with cancer cells employing embryonic pathways by which to enhance motility and invasion. Importantly, features of oncogenic EMT correlate with clinical parameters, suggesting that reactivation of the developmental EMT program in cancer contributes to cancer progression. 13, 14 Therefore, EMT is hypothesized to contribute to tumor progression, and indeed clinical evidence suggests that regulators of EMT in cancer cells correlate with poor patient outcomes and tumor aggressiveness. 15 Esophageal cancer is the eighth most commonly occurring cancer and the sixth leading cause of cancer-related death in the world, with the majority of cases occurring in developing countries. The pathological significance of EMT in the development of ESCC is becoming increasingly recognized; however, the underlying process is poorly understood. The present findings directly show that Akt plays an essential role in TGF-b1-mediated EMT in human ESCC.
EMT is a result of the activation of signaling pathways through membrane-associated proteins. Over the last 15 years, TGF-b has been shown to function as a potent inducer of EMT, with its signaling pathways intimately involved in the activation and progression of EMT. 16 During the early stages of tumor growth, TGF-b seems to act as a tumor suppressor by inducing growth arrest and apoptosis. During tumor progression, the growth inhibitory response to TGF-b is decreased, whereas the EMT response is retained or even increased. 17, 18 For example, TGF-b stimulates EMT in vitro in Namru murine mammary gland and mouse proximal tubule kidney epithelial cells, 19 in immortalized human keratinocytes HaCaT, 20 as well as in human colonic and hepatocellular carcinomas. 21 Malignant keratinocytes expressing Ras oncogenes exhibit stronger EMT and architectural depolarization, which is mediated by TGF-b and appears more similar to the response described here for normal mammary cells. 22 In this study, we showed that the expression of TGF-b1 induced EMT in EC-9706 cells and was accompanied by the increased metastatic and invasion properties of EC-9706. EMT is marked by the change in cell morphology: epithelial cells acquire mesenchymal properties and show loss of cell-cell cohesion. Our results showed that the morphology of EC-9706 cells treated with TGF-b1 changed from a typical epithelial shape to fibroblast-like shape. As many of the junction complex proteins characterize epithelial cells, the dissolution of the junctions results in a loss of many epithelial marker proteins. Among them, decrease in E-cadherin expression has become a major indication of loss of epithelial characteristics. In EMT, the loss of epithelial markers is accompanied by an induction of the expression of mesenchymal The role of Akt in EMT X Xuan et al proteins, such as Vimentin. In our study, the expression of E-cadherin was decreased in EC-9706 cells after treatment with TGF-b1 for 24 h. In contrast to E-cadherin, Vimentin expression is induced by TGF-b1. In addition, our data also showed that TGF-b1 was a strong inducer of tumor cell metastasis. By Boyden invasion chamber assay, we found that EC-9706 cells treated with TGF-b1 had a significant decrease in the number of cells that traversed the matrigel-coated membrane. Thus, we can see that TGF-b1 induces EMT in EC-9706 cells and by EMT to promote EC-9706 cell metastasis and invasion. The induction of EMT in response to TGF-b has been attributed in part to the Smad transcription complexes that regulate transcription of essential genes involved in this process. In addition to Smad signaling, 23 TGF-b can initiate non-Smad signaling pathways such as the phosphoinositide 3K-Akt pathway, the Ras/MAP kinase, and Jagged/Notch. These pathways also play an essential role in mediating TGF-b stimulation of EMT, invasion and metastasis. For example, it is known that the phosphoinositide 3K/ Akt signaling pathway serves to regulate EMT of hepatocellular carcinoma cells. The Akt pathway can promote survival through the inactivation of proapoptotic proteins. 24 The anti-apoptotic effect of TGF-b1 observed in some systems may be explained by Akt activation. The functions of Akt are pleiotropic and it has emerged as an important player in the signaling cascades that regulate cell growth, proliferation, differentiation, protein synthesis and survival, as well as angiogenesis, invasion and metastasis. Akt can also induce EMT by upregulating the expression of Snail through phosphorylating GSK-3. 25, 26 However, few reports have investigates the function of Akt in EMT in ESCC. In the present study, through immunohistochemical analysis we also showed that positive expression of Akt and of its active form p-Akt protein in ESCC tissues was significantly higher than in corresponding normal esophageal mucosa and that Akt and p-Akt were negatively correlated with E-cadherin.
To examine whether the expression of TGF-b1 activates the Akt signailing pathway in EC-9706 cells, we measured the phosphorylation of Akt in cells treated with TGF-b1 after 24 h and in their corresponding parental cells. We found that expression of Akt was significantly higher in EC-9706 cells treated with TGF-b1. Together, our results indicate that expression of TGF-b1 can induce the activation of Akt.
After identifying the relationship between TGF-b1 stimulation and the upregulation of Akt, we determined whether Akt was a key factor in the EMT induced by TGF-b1. Akt siRNA was chemically synthesized and transfected into EC-9706 cells after the EC-9706 cells were treated with TGF-b1 for 24 h. Then, reverse transcription-PCR and western blot were applied to detect the changes in mRNA and protein expressions of Akt, E-cadherin and Vimentin after EC-9706 cells were stimulated with TGF-b1 and transfected with Akt siRNA or TGF-b1 combined with Akt siRNA treatment. Treatment of EC-9706 cells with both TGF-b1 and Akt siRNA partly restores their epithelial morphology. Simultaneously, we found that downregulation of Akt by Akt siRNA decreased the expression of the mesenchymal marker Vimentin, suggesting that Akt is involved in maintaining the mesenchymal properties of EC-9706 cell treated with TGF-b1. At the same time, we found that silencing the expression of Akt by Akt siRNA increased the expression of E-cadherin significantly after TGF-b1 stimulation, indicating that Akt has important functions in preserving the cellcell adhesion in EC-9706 cells. These results showed that there was a functional linkage between Akt expression and TGF-b1-mediated EMT in EC-9706 cells and these results confirm that the Akt pathway is essential for the EMT induced by TGF-b1 because inhibition of the expression of Akt by siRNA can prevent TGF-b1-induced EMT efficiently.
Thereafter, by using the Boyden invasion chamber assay, we found that the downregulation of Akt can reduce the metastatic and invasive ability of EC-9706 after TGF-b1 stimulation.
In conclusion, our data suggest that exogenous TGF-b1 can induce an EMT-like alteration in EC-9706 cells and enhance cell invasive ability in vitro. Meanwhile, Akt siRNA can intercept the malignant transition promoted by TGF-b1, further highlighting the important role of Akt during the process of invasion and metastasis in ESCC. Akt may be an effective therapeutic or chemopreventative strategy in advanced and metastatic ESCC.
